1887

Journal of Medical Microbiology logo

Volume 70, Issue 8

Validation of Pefloxacin for detection of fluoroquinolone (FQ) resistance among Typhi with special reference to GyrB mutations No Access

Abstract

Fluoroquinolone (FQ) resistant are classified as high priority pathogens by WHO. FQ resistance among Typhi has emerged rapidly and is predominantly mediated by mutations in the topoisomerase genes , and . Mutations in GyrA result in classical FQ resistance (DCS-NAR) i.e. decreased susceptibility to ciprofloxacin (MIC of 0.12 to 0.5 µg ml) (DCS) and resistance to nalidixic acid (NAR). Previously a nalidixic acid disc test was proposed for detection of DCS. Recently isolates with non-classical FQ resistance caused by plasmid-mediated quinolone resistance (PMQR) and mutations in GyrB have emerged. These mechanisms also result in DCS but are nalidixic acid susceptible (NAS) and thus pose diagnostic challenges. CLSI and EUCAST have recommended use of 5 µg pefloxacin discs for detection of DCS in .

The CLSI and EUCAST recommendations for use of 5 µg pefloxacin for detection of DCS has not been validated on typhoidal and resistance mediated by GyrB mutation in species.

The aim of the present study was to validate the performance of the 5 µg pefloxacin discs to detect isolates of . Typhi with DCS with special reference to GyrB mutations.

A total of 180 clinical isolates of Typhi (2005–2014) were investigated for genetic mechanisms of resistance. Zone diameters for nalidixic acid (30μg), ciprofloxacin (5μg) and pefloxacin (5µg) and minimum inhibitory concentration (MIC) for ciprofloxacin were determined using CLSI guidelines. Performance of the three discs was evaluated to detect FQ resistance in . Typhi.

Topoisomerase mutations in GyrB +/ ParC and GyrB were detected in 112 and 34 isolates respectively. Different mutations have a varied effect on the MIC for ciprofloxacin. The current breakpoints for susceptible (≤0.06 µg ml) and non-susceptible (≥0.125 µg ml), failed to detect all isolates with a resistance mechanism. Performance of both ciprofloxacin and pefloxacin discs were excellent compared to nalidixic acid in differentiating isolates with non-classical resistance mediated by GyrB from wild-type.

The pefloxacin disc can be used to detect FQ resistance among . Typhi. This is the first report of validation of pefloxacin for detection of FQ resistance in . Typhi mediated by GyrB mutation.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Decreased ciprofloxacin susceptibility (DCS) , GyrB mutation , Non-classical fluroquinolone resistance , Pefloxacin , quinolone resistance determining region (QRDR) and Salmonella Typhi
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001398
2021-08-06
2024-05-03
Loading full text...

Full text loading...

References

  1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346–353 [PubMed]
     [Google Scholar]
  2. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347:1770–1782 [View Article] [PubMed]
     [Google Scholar]
  3. Parry CM, Basnyat B, Crump JA. The management of antimicrobial-resistant enteric fever. Expert Rev Anti Infect Ther 2013; 11:1259–1261 [View Article] [PubMed]
     [Google Scholar]
  4. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi Salmonellae. Clin Infect Dis 2003; 37:75–81 [View Article] [PubMed]
     [Google Scholar]
  5. Sjolund-Karlsson M, Folster JP, Pecic G, Joyce K, Medalla F et al. Emergence of plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates from humans in the United States. Antimicrob Agents Chemother 2009; 53:2142–2144 [View Article] [PubMed]
     [Google Scholar]
  6. Stevenson JE, Gay K, Medalla F, Chiller TM, Angulo FJ. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother 2007; 51:195–197 [View Article] [PubMed]
     [Google Scholar]
  7. Threlfall EJ, Skinner JA, Ward LR. Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. Antimicrob Chemother 2001; 48:740–741 [View Article]
     [Google Scholar]
  8. WHO 2019 https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1, https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/
  9. Tacconelli E, Carrara E, Savoldi A, Harbarth MS et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318–327 [View Article] [PubMed]
     [Google Scholar]
  10. Gupta R, Gaind R, Wain J, Deb M, Singh LC et al. Characterization of non-classical quinolone resistance in Salmonella enterica serovar Typhi: Report of a novel mutation in gyrB gene and diagnostic challenges. Biomol Detect Quantif 2015; 2:30–34 [View Article] [PubMed]
     [Google Scholar]
  11. Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S et al. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi a causing enteric fever in India. Journal of Antimicrobial Chemotherapy 2006; 58:1139–1144 [View Article]
     [Google Scholar]
  12. Cooke FJ, Wain J, Threlfall EJ. Fluoroquinolone resistance in Salmonella Typhi. BMJ 2006; 333:353–354 [View Article]
     [Google Scholar]
  13. Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6′)Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J Clin Microbiol 2009; 47:2751–2758 [View Article] [PubMed]
     [Google Scholar]
  14. Accou-Demartin M, Gaborieau V, Song Y, Roumagnac P, Marchou B et al. Salmonella enterica serotype typhi with nonclassical quinolone resistance phenotype. Emerg Infect Dis 2011; 17:1091–1094 [View Article] [PubMed]
     [Google Scholar]
  15. Sjölund-Karlsson M, Howie R, Rickert R, Krueger A, Tran T-T et al. Plasmid-mediated quinolone resistance among non-typhi Salmonella enterica isolates, USA. Emerg Infect Dis 2010; 16:1789–1791 [View Article] [PubMed]
     [Google Scholar]
  16. Walia M, Gaind R, Mehta R, Paul P, Aggarwal P et al. Current perspectives of enteric fever: a hospital-based study from. India 2013; 25:161–174 [View Article]
     [Google Scholar]
  17. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404–1410 [View Article]
     [Google Scholar]
  18. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid mediated quinolone resistance: a multifaceted threat. Clin MicrobiolRev 2009; 22:664–689 [View Article] [PubMed]
     [Google Scholar]
  19. Gay K, Robics A, Strahilevitz J, Park CH, Jacoby G et al. Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis 2006; 43:297–304 [View Article]
     [Google Scholar]
  20. Wayne PA. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing: 25th Informational Supplement, CLSI document m100-25. 2015
     [Google Scholar]
  21. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of mics and zone diameters. Version 4.0. 2014; 2021 http://www.eucast.org/clinical_breakpoints/
  22. Wayne PA. Clinical and Laboratory Standards Institute Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters—4th ed. M23-A4 Clinical and Laboratory Standards Institute; 2016
     [Google Scholar]
  23. Deak E, Skov R, Janet A, Hindler J, Humphries RM. Evaluation of surrogate disk tests for detection of ciprofloxacin and levofloxacin resistance in clinical isolates of Salmonella enterica. J Clin Microbiol 2015; 53:3405–3410 [View Article]
     [Google Scholar]
  24. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859–865 [View Article] [PubMed]
     [Google Scholar]
  25. Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ. Cases of typhoid fever imported to England, Scotland and Wales (2000–2003). Trans R Soc Trop Med Hyg 2007; 101:398–404 [View Article] [PubMed]
     [Google Scholar]
  26. Skov R, Matuschek E, Sjölund-Karlsson M, Åhman J, Petersen A et al. Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica. J Clin Microbiol 2015; 53:3411–3417 [View Article] [PubMed]
     [Google Scholar]
  27. Sharma P, Dahiya S, Kumari B, Balaji V, Kapil A et al. Pefloxacin as a surrogate marker for quinolone susceptibility in Salmonella enterica serovars Typhi & Paratyphi A in India. Indian J Med Res 2017; 145:687–692 [View Article] [PubMed]
     [Google Scholar]
  28. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive salmonella infections. Clin Microbiol Rev 2015; 28:901–937 [View Article] [PubMed]
     [Google Scholar]
  29. Parry CM, Chau TT, Dongol S, Karkey A et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54:5201–5208 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001398
Loading
Validation of Pefloxacin for detection of fluoroquinolone (FQ) resistance among Salmonella Typhi with special reference to GyrB mutations
J. Med. Microbiol. 70, 001398 (2021); https://doi.org/10.1099/jmm.0.001398
/content/journal/jmm/10.1099/jmm.0.001398
/content/journal/jmm/10.1099/jmm.0.001398
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error